Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company hopes to follow on from Keytruda's success after Merck's drug won a groundbreaking FDA approval last year based on biomarkers rather than tumor location.
08.02.2018
NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology
More news
13.11.2026
NeoPhore strengthens leadership as it prepares to take first-in-class DNA mismatch repair inhibitor into the clinic
Marianne Bjordal appointed CEO; Judit Molnar promoted to Chief Development Officer London, UK, 13 November 2026 – NeoPhore Limited, a company …
21.04.2026
AACR 2026 and AACR Cancer Discovery Article
NeoPhore Press Release: AACR 2026 and AACR Cancer Discovery Article London UK, 21 April 2026 NeoPhore, an immuno-oncology company, announces the …
16.09.2025
NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025
NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …